Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide
| Autor: | S Shaunak, D J Dick, J B Pilling, Alastair Wilkins |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Male
medicine.medical_specialty Parkinson's disease medicine.medical_treatment Short Report Retroperitoneal fibrosis Antiparkinson Agents Fibrosis medicine Humans Pericardium Adverse effect Aged Pergolide Chemotherapy medicine.diagnostic_test business.industry Parkinson Disease Retroperitoneal Fibrosis Middle Aged medicine.disease Surgery Psychiatry and Mental health medicine.anatomical_structure Erythrocyte sedimentation rate Pleura Neurology (clinical) medicine.symptom business medicine.drug |
| Zdroj: | Journal of Neurology, Neurosurgery & Psychiatry. 66:79-81 |
| ISSN: | 0022-3050 |
| DOI: | 10.1136/jnnp.66.1.79 |
| Popis: | Three patients with Parkinson's disease are described who developed pericardial, retroperitoneal, and pleural fibrosis associated with pergolide treatment. Surgical intervention was required in all three cases, either to reach a tissue diagnosis or for potentially life threatening complications. Symptoms emerged on average 2years after the institution of treatment, and were sufficiently non-specific to cause significant delays in diagnosis in all cases. The erythrocyte sedimentation rate (ESR) was raised in the two patients in whom it was measured. Serosal fibrosis is a rarely reported adverse effect of pergolide treatment, although it is well described with other dopamine agonists. We suggest that patients with Parkinson's disease who receive pergolide treatment should be regularly monitored for the development of such complications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|